| Orlando J Andy, MD | |
|
415 S 28th Ave, Hattiesburg, MS 39401-7246 | |
| (601) 268-5660 | |
| (601) 268-5759 |
| Full Name | Orlando J Andy |
|---|---|
| Gender | Male |
| Speciality | General Surgery |
| Experience | 36 Years |
| Location | 415 S 28th Ave, Hattiesburg, Mississippi |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1659395838 | NPI | - | NPPES |
| 020019577 | Other | RAILROAD MEDICARE | |
| 1558917 | Other | MS | AMERICAN ADMIN GROUP |
| 1419711 | Medicaid | LA | |
| 00112019 | Medicaid | MS |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 208600000X | Surgery | 12082 (Mississippi) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Forrest General Hospital | Hattiesburg, MS | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Hattiesburg Clinic, Pa | 5193706794 | 489 |
News Archive
Drugs that enhance a process called oxidative stress were found to kill rhabdomyosarcoma tumor cells growing in the laboratory and possibly bolstered the effectiveness of chemotherapy against this aggressive tumor of muscle and other soft tissue. The findings are the latest from the St. Jude Children's Research Hospital-Washington University Pediatric Cancer Genome Project and appear in the December 9 edition of the scientific journal Cancer Cell.
RayBiotech, Inc. has announced the winners of its Biomarker Discovery Pilot Grant program. In total, 18 award recipients were chosen for grants of up to $20,000 each, redeemable for RayBiotech products and services. "By offering these grants," states Dr. Ray (Ruopan) Huang, Founder and President of RayBiotech, "we intend to demonstrate that any researcher with a modest research budget can successfully discover and validate disease-related biomarkers using our antibody arrays."
ARIAD Pharmaceuticals, Inc. today announced that the Committee for Medicinal Products for Human Use of the European Medicines Agency has adopted its final opinion on Iclusig (ponatinib) following the recommendations made by the Pharmacovigilance Risk Assessment Committee earlier this month.
Targacept, Inc., a clinical-stage biopharmaceutical company developing novel NNR Therapeutics, today announced top-line results from two separate exploratory Phase 2 studies of its product candidate TC-6987 conducted in the United States, one in asthma and one in type 2 diabetes.
Locally-sourced antibiotics can be as effective as 'internationally quality-assured' (IQA) antibiotics for treating multidrug-resistant tuberculosis (MDR-TB) in Pakistan, and may help avoid delays in starting treatment while programmes wait for drugs to arrive from overseas, according to new research published in PLOS ONE.
› Verified 4 days ago
| Entity Name | Hattiesburg Clinic Pa |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1740213446 PECOS PAC ID: 5193706794 Enrollment ID: O20040528000685 |
News Archive
Drugs that enhance a process called oxidative stress were found to kill rhabdomyosarcoma tumor cells growing in the laboratory and possibly bolstered the effectiveness of chemotherapy against this aggressive tumor of muscle and other soft tissue. The findings are the latest from the St. Jude Children's Research Hospital-Washington University Pediatric Cancer Genome Project and appear in the December 9 edition of the scientific journal Cancer Cell.
RayBiotech, Inc. has announced the winners of its Biomarker Discovery Pilot Grant program. In total, 18 award recipients were chosen for grants of up to $20,000 each, redeemable for RayBiotech products and services. "By offering these grants," states Dr. Ray (Ruopan) Huang, Founder and President of RayBiotech, "we intend to demonstrate that any researcher with a modest research budget can successfully discover and validate disease-related biomarkers using our antibody arrays."
ARIAD Pharmaceuticals, Inc. today announced that the Committee for Medicinal Products for Human Use of the European Medicines Agency has adopted its final opinion on Iclusig (ponatinib) following the recommendations made by the Pharmacovigilance Risk Assessment Committee earlier this month.
Targacept, Inc., a clinical-stage biopharmaceutical company developing novel NNR Therapeutics, today announced top-line results from two separate exploratory Phase 2 studies of its product candidate TC-6987 conducted in the United States, one in asthma and one in type 2 diabetes.
Locally-sourced antibiotics can be as effective as 'internationally quality-assured' (IQA) antibiotics for treating multidrug-resistant tuberculosis (MDR-TB) in Pakistan, and may help avoid delays in starting treatment while programmes wait for drugs to arrive from overseas, according to new research published in PLOS ONE.
› Verified 4 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Orlando J Andy, MD 415 S 28th Ave, Hattiesburg, MS 39401-7246 Ph: (601) 268-5660 | Orlando J Andy, MD 415 S 28th Ave, Hattiesburg, MS 39401-7246 Ph: (601) 268-5660 |
News Archive
Drugs that enhance a process called oxidative stress were found to kill rhabdomyosarcoma tumor cells growing in the laboratory and possibly bolstered the effectiveness of chemotherapy against this aggressive tumor of muscle and other soft tissue. The findings are the latest from the St. Jude Children's Research Hospital-Washington University Pediatric Cancer Genome Project and appear in the December 9 edition of the scientific journal Cancer Cell.
RayBiotech, Inc. has announced the winners of its Biomarker Discovery Pilot Grant program. In total, 18 award recipients were chosen for grants of up to $20,000 each, redeemable for RayBiotech products and services. "By offering these grants," states Dr. Ray (Ruopan) Huang, Founder and President of RayBiotech, "we intend to demonstrate that any researcher with a modest research budget can successfully discover and validate disease-related biomarkers using our antibody arrays."
ARIAD Pharmaceuticals, Inc. today announced that the Committee for Medicinal Products for Human Use of the European Medicines Agency has adopted its final opinion on Iclusig (ponatinib) following the recommendations made by the Pharmacovigilance Risk Assessment Committee earlier this month.
Targacept, Inc., a clinical-stage biopharmaceutical company developing novel NNR Therapeutics, today announced top-line results from two separate exploratory Phase 2 studies of its product candidate TC-6987 conducted in the United States, one in asthma and one in type 2 diabetes.
Locally-sourced antibiotics can be as effective as 'internationally quality-assured' (IQA) antibiotics for treating multidrug-resistant tuberculosis (MDR-TB) in Pakistan, and may help avoid delays in starting treatment while programmes wait for drugs to arrive from overseas, according to new research published in PLOS ONE.
› Verified 4 days ago
Dr. William Duncan Donald Iii, M.D. Surgery Medicare: Accepting Medicare Assignments Practice Location: 6051 Us Hwy 49, Hattiesburg, MS 39401 Phone: 601-288-2690 Fax: 601-288-2695 | |
Ralph E Abraham, MD Surgery Medicare: Not Enrolled in Medicare Practice Location: 415 S 28th Ave, Hattiesburg, MS 39401 Phone: 601-268-5660 Fax: 601-268-5759 | |
Petra R Schneider-redden, MD Surgery Medicare: Accepting Medicare Assignments Practice Location: 421 S 28th Ave, Hattiesburg, MS 39401 Phone: 601-261-3690 Fax: 601-261-3684 | |
Dr. Cesar R Romero, MD Surgery Medicare: Not Enrolled in Medicare Practice Location: 6051 U S Highway 49, Hattiesburg, MS 39401 Phone: 601-288-2690 Fax: 601-288-2695 | |
Dr. Kirk J Banquer, M.D. Surgery Medicare: Not Enrolled in Medicare Practice Location: 6051 U S Highway 49, Hattiesburg, MS 39401 Phone: 601-288-2690 Fax: 601-288-2695 | |
Rachel Kaitlin Rosado, D.O. Surgery Medicare: Accepting Medicare Assignments Practice Location: 415 S 28th Ave, Hattiesburg, MS 39401 Phone: 601-268-5660 | |
Robert A Stringer, M.D. Surgery Medicare: Accepting Medicare Assignments Practice Location: 6051 U S Highway 49, Hattiesburg, MS 39401 Phone: 601-288-2690 Fax: 601-288-2695 |